A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

← catalyst calendar

NCT07160725 · readout in 712 d

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

540estimated

Sites

Countries

China, Denmark, Japan +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-10-15

actual

When the study began enrolling

Primary completion

2028-07-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-08-01

estimated

The whole study's end, after follow-up

First posted

2025-09-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Solid Tumours

Interventions

Drug: BMS-986517
Drug: Pumitamig — also filed as BMS-986545, BNT327, PMS002

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Adverse Events (AE)

measured Up to approximately 2 years

Number of Participants with Serious Adverse Events (SAE)

measured Up to approximately 2 years

Number of Participants with AEs meeting protocol-defined Dose-limiting Toxicities (DLTs) criteria

measured Up to Day 21

Number of Participants with AEs Leading to Discontinuation

measured Up to approximately 2 years

Number of Participants with AEs Leading to Deaths

measured Up to approximately 2 years

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed